1. Home
  2. MGNX vs BAER Comparison

MGNX vs BAER Comparison

Compare MGNX & BAER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • BAER
  • Stock Information
  • Founded
  • MGNX 2000
  • BAER 2014
  • Country
  • MGNX United States
  • BAER United States
  • Employees
  • MGNX N/A
  • BAER N/A
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • BAER Blank Checks
  • Sector
  • MGNX Health Care
  • BAER Finance
  • Exchange
  • MGNX Nasdaq
  • BAER Nasdaq
  • Market Cap
  • MGNX 87.7M
  • BAER 100.7M
  • IPO Year
  • MGNX 2013
  • BAER N/A
  • Fundamental
  • Price
  • MGNX $1.33
  • BAER $1.66
  • Analyst Decision
  • MGNX Hold
  • BAER Strong Buy
  • Analyst Count
  • MGNX 9
  • BAER 1
  • Target Price
  • MGNX $5.33
  • BAER $5.25
  • AVG Volume (30 Days)
  • MGNX 2.0M
  • BAER 229.0K
  • Earning Date
  • MGNX 08-05-2025
  • BAER 08-11-2025
  • Dividend Yield
  • MGNX N/A
  • BAER N/A
  • EPS Growth
  • MGNX N/A
  • BAER N/A
  • EPS
  • MGNX N/A
  • BAER N/A
  • Revenue
  • MGNX $154,050,000.00
  • BAER $108,752,000.00
  • Revenue This Year
  • MGNX N/A
  • BAER $13.26
  • Revenue Next Year
  • MGNX N/A
  • BAER N/A
  • P/E Ratio
  • MGNX N/A
  • BAER N/A
  • Revenue Growth
  • MGNX 255.31
  • BAER 51.36
  • 52 Week Low
  • MGNX $0.99
  • BAER $1.02
  • 52 Week High
  • MGNX $5.77
  • BAER $4.44
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 41.45
  • BAER 48.74
  • Support Level
  • MGNX $1.33
  • BAER $1.79
  • Resistance Level
  • MGNX $2.17
  • BAER $1.94
  • Average True Range (ATR)
  • MGNX 0.17
  • BAER 0.12
  • MACD
  • MGNX -0.02
  • BAER -0.02
  • Stochastic Oscillator
  • MGNX 2.38
  • BAER 12.50

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About BAER Bridger Aerospace Group Holdings Inc.

Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Bridger Aerospace provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation. The company's portfolio is organized across two offerings: Fire Suppression, which Consists of deploying specialized Viking CL-415EAF (Super Scooper) aircraft to drop large amounts of water quickly and directly on wildfires, and Aerial Surveillance, providing aerial surveillance via manned aircraft for fire suppression aircraft.

Share on Social Networks: